# BEAM — slm-full-cpu

## Metadata

ticker: BEAM
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 21a3ddfff049e620d1a983f1331dba3a68bee0dd1c8cc144c5039f435e485096
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 764, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 193.416, "latency_s_total": 193.416, "parse_failure": 0, "prompt_tokens": 3093, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 474, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 144.015, "latency_s_total": 144.015, "parse_failure": 0, "prompt_tokens": 2340, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 140, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 48.384, "latency_s_total": 48.384, "parse_failure": 0, "prompt_tokens": 678, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 135, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 76.015, "latency_s_total": 76.015, "parse_failure": 0, "prompt_tokens": 672, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 220, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 89.375, "latency_s_total": 89.375, "parse_failure": 0, "prompt_tokens": 546, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 142, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 88.96, "latency_s_total": 88.96, "parse_failure": 0, "prompt_tokens": 844, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 945, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 111.532, "latency_s_total": 111.532, "parse_failure": 0, "prompt_tokens": 1652, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 25.67,
  "currency": "USD",
  "market_cap": 2651394304.0,
  "forward_pe": -5.414047,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "financial_currency": "USD",
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin_pct": -55.45,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided risk factors from the Annual Report on Form 10-K for BEAM, the key takeaways regarding the company's financial position, operational status, and future outlook are as follows:

**Financial Performance and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** BEAM expects to incur significant expenses and increasing operating losses for the foreseeable future. The company will need substantial additional funding to support research and development, clinical trials, and potential commercialization efforts.
*   **Liquidity Position:** As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities. Management believes this amount is sufficient to fund operating expenses and capital expenditures for at least the next 12 months, though this may change due to unknown factors.
*   **No Committed Capital Sources:** Aside from a credit facility with Sixth Street Lending Partners, the company has no committed external source of additional capital. Failure to raise capital on acceptable terms could force the company to delay, reduce, or eliminate research programs or commercialization efforts.

**Operational Status and Product Development**
*   **Early-Stage Development:** BEAM is an early-stage company founded in 2017. It has not yet completed any pivotal clinical trials, obtained marketing approvals, or commercialized any medicines.
*   **High Risk of Failure:** Many product development programs are in early clinical, preclinical, or research stages, carrying a high risk of failure. The company has not demonstrated the ability to successfully complete pivotal trials, manufacture commercial-scale medicines, or conduct sales and marketing activities.
*   **Past Restructuring:** In October 2023, the company announced a portfolio repriorization and strategic restructuring, which resulted in the pausing or elimination of certain pipeline programs to reduce operating expenses.

**Risks Related to Dilution and Agreements**
*   **Stockholder Dilution:** Raising additional capital through equity or convertible debt offerings will dilute existing stockholders. Future issuances of shares to partners and collaborators for milestone payments may also cause substantial dilution.
*   **Restrictive Covenants:** The financing agreement with Sixth Street Lending Partners includes covenants that restrict actions such as incurring additional debt, making capital expenditures, and declaring dividends.
*   **License and Collaboration Risks:** The company may be forced to seek collaborators at earlier stages than desired or on less favorable terms. Current and future license agreements may be terminated if the company fails to meet payment or other obligations. Additionally, the company faces potential success liabilities to Harvard and the Broad Institute.

**Long-Term Viability**
*   **Uncertain Path to Profitability:** The company does not expect to generate significant revenues for years, if ever. It is unable to predict when it will become profitable, if at all, due to the numerous risks associated with developing base editing product candidates. Failure to achieve profitability could impair the company's ability to raise capital and continue operations.
*   **Short Operating History:** With a short history as an operating company in a rapidly evolving field, it is difficult to evaluate the company's technology, industry position, or future performance.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Losses and Need for Capital:** The company has incurred significant operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. It expects to continue incurring significant expenses and operating losses for the foreseeable future and may never achieve profitability. Consequently, the company requires substantial additional funding to support operations, research, and development.
*   **Inability to Achieve Profitability:** The company has not yet commercialized any products and has not completed any pivotal clinical trials. It faces numerous risks and uncertainties in developing base editing product candidates, and even if it achieves profitability, it may not be able to sustain or increase it. Failure to become profitable could impair the company’s ability to raise capital, maintain R&D efforts, or continue operations.
*   **Operational and Development Risks:** The company has not demonstrated the ability to successfully complete pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale medicines, or conduct necessary sales and marketing activities. The drug development process is time-consuming, expensive, and uncertain, taking approximately 10 to 15 years from discovery to patient availability.
*   **Limited Operating History:** As a relatively new company in the rapidly evolving base editing and gene editing field, the company has a short operating history, making it difficult to evaluate its technology, industry, and future performance. It faces risks and difficulties typical of early-stage companies in rapidly evolving fields.
*   **Dependence on External Funding:** The company has no committed source of additional capital other than its credit facility with Sixth Street Lending Partners. If it cannot raise capital on acceptable terms, it may be forced to delay, reduce, or eliminate research and product development programs or commercialization efforts. This could also lead to the termination of current and future license and collaboration agreements if payment obligations are not met.
*   **Past Strategic Changes:** The company has previously delayed, reduced, or eliminated research and product development programs to decrease operating expenses, such as through the portfolio reprioritization and strategic restructuring announced in October 2023.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc. (BEAM) currently trades at $25.67 with a market capitalization of approximately $2.65 billion. The company reported revenue of $156.04 million, but continues to operate with a negative net income of $86.52 million, resulting in a profit margin of -55.45%. Consequently, the forward P/E ratio is negative, reflecting ongoing losses rather than profitability. This financial profile indicates a high-risk, pre-profitability stage typical of biotechnology firms heavily invested in R&D. Investors should monitor future revenue growth and cash burn rates closely as key indicators of financial sustainability.

### Recent Developments

Beam Therapeutics Inc. recently filed its 2025 Annual Report on Form 10-K on February 24, 2026, and its Q2 2026 Quarterly Report on Form 10-Q on August 4, 2026. Both filings prominently highlight significant risk factors that could materially adversely affect the company's business, financial condition, and operating results. Investors should carefully review these disclosures, as they underscore ongoing uncertainties and potential threats to the company's stability. The absence of specific operational news in the provided data suggests that regulatory and financial risks remain the primary focus for stakeholders.

### SEC Filing Highlights
Beam Therapeutics reported a net loss of $80.0 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it continues to operate at a loss. The company holds $1.2 billion in cash and marketable securities, which management believes is sufficient to fund operations for at least the next 12 months. Despite this liquidity, BEAM remains an early-stage developer with no approved products or completed pivotal trials, facing significant risks of failure in its base editing pipeline. Future capital needs will likely require equity or debt financing, which could result in substantial dilution to existing stockholders.

### Risk Factors

*   **Persistent Financial Losses and Capital Dependency:** The company has incurred significant operating losses (e.g., $376.7 million in 2024) and has not yet achieved profitability. It relies heavily on external funding to sustain operations, and an inability to raise capital on acceptable terms could force the delay or termination of research programs and commercialization efforts.
*   **Early-Stage Development and Commercialization Uncertainty:** BEAM has not commercialized any products or completed pivotal clinical trials. The drug development process is highly uncertain, time-consuming, and expensive, with no guarantee that base editing candidates will receive regulatory approval or achieve market success.
*   **Limited Operating History and Strategic Volatility:** As a relatively new player in the gene editing field, the company has a short track record, making it difficult to evaluate its long-term viability. This risk is compounded by past strategic restructuring, including the reprioritization and elimination of certain development programs in 2023, which highlights the inherent instability of early-stage biotech portfolios.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. is a pre-profitability biotechnology firm specializing in base editing, currently trading at $25.67 with a market capitalization of approximately $2.65 billion and an accumulated deficit of $1.6 billion. The stock is notable for its high-risk profile, characterized by significant operating losses and a reliance on its $1.2 billion cash reserve to fund operations while navigating a pipeline with no approved products or completed pivotal trials. The single most important near-term variable shaping the outcome is the company’s ability to successfully advance its base editing candidates through clinical development without exhausting its liquidity or requiring dilutive capital raises.

### Outlook
The directional outlook for Beam Therapeutics is cautiously constructive but heavily contingent on binary clinical milestones and capital management. While the company possesses a substantial cash runway, the absence of approved products and completed pivotal trials creates significant headwinds, requiring investors to closely monitor the progression of its base editing pipeline and any potential strategic reprioritizations. Tailwinds would emerge from positive clinical data that validates the platform’s efficacy, whereas headwinds would intensify if cash burn accelerates or if regulatory hurdles delay trial timelines. The investment thesis remains sensitive to the company’s ability to navigate these early-stage risks without triggering dilutive financing events, making clinical progress and liquidity preservation the primary variables to watch.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "currently trading at $25.67"
LABEL: SUPPORTED
REASON: The source data explicitly lists `"current_price": 25.67`.

---

CLAIM: "market capitalization of approximately $2.65 billion"
LABEL: SUPPORTED
REASON: Source data shows `"market_cap": 2651394304.0`, which rounds to approximately $2.65 billion.

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "the accumulated deficit stood at $1.6 billion" as of December 31, 2025.

---

CLAIM: "$1.2 billion cash reserve to fund operations"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "the company held $1.2 billion in cash, cash equivalents, and marketable securities."

---

CLAIM: "no approved products or completed pivotal trials"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states BEAM "has not yet completed any pivotal clinical trials, obtained marketing approvals, or commercialized any medicines."

---

**OUTLOOK**

---

CLAIM: "the company possesses a substantial cash runway"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights states the $1.2 billion in cash is "sufficient to fund operating expenses and capital expenditures for at least the next 12 months," directly supporting the characterization of a substantial cash runway.

---

CLAIM: "the absence of approved products and completed pivotal trials"
LABEL: SUPPORTED
REASON: Directly corroborated by the RAG — SEC Highlights and the SEC Filing Highlights pre-written section, both of which confirm no approved products or completed pivotal trials exist.

---

*No additional quantitative figures, price targets, thresholds, ratios, specific percentages, named product milestones, or forward-looking numbers appear in the Outlook section beyond those already evaluated above. All qualitative directional statements (e.g., "cautiously constructive," "binary clinical milestones," "dilutive financing events") are non-quantitative and fall outside the scope of this audit.*
